eligibility_summary
Eligibility: adults ≥18, ECOG 0–1, recurrent measurable grade 4 GBM/diffuse astrocytoma after standard therapy and ≥12 wks post-RT, MMP2+ by IHC (≥20% 2+/3+), adequate labs and venous access, HIV/HBV/HCV negative, contraception/neg pregnancy, no leukapheresis/steroid contraindications. Exclude: recent bevacizumab, unresolved toxicity, uncontrolled seizures/encephalopathy, active infection/serious illness, allergy, other malignancy, pregnancy/breastfeeding, noncompliance/unsafe.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05627323 tests CHM-1101, an autologous CAR T-cell therapy (biologic, cell therapy) engineered with a chlorotoxin (CLTX) tumor-targeting domain that binds the MMP2 complex on glioblastoma. The CAR uses CD28 costimulation and CD3ζ signaling to activate T cells and includes a truncated CD19 tag for selection/tracking. After resection, cells are delivered locally via intracavitary/intratumoral and intraventricular catheters in weekly doses. Target: MMP2-positive glioblastoma cells, pathway focus is the matrix metalloproteinase-2–associated surface complex driving tumor invasion, enabling CAR T-mediated cytotoxic killing within tumor/CSF compartments.